ARTICLE | Clinical News
Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong
August 3, 2018 5:37 PM UTC
Ascletis Pharma Inc. (HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein inhibitor.
In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to the HCV NS3/4A protease inhibitor from Roche (SIX:ROG; OTCQX:RHHBY) in China, Hong Kong, Macau and Taiwan...
BCIQ Company Profiles